Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
Saved in:
| Title: | Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. |
|---|---|
| Authors: | Gordon, Kenneth B1 (AUTHOR) gordon.kenneth@att.net, Langley, Richard G2 (AUTHOR), Warren, Richard B3,4 (AUTHOR), Okubo, Yukari5 (AUTHOR), Rosmarin, David6 (AUTHOR), Lebwohl, Mark7 (AUTHOR), Peterson, Luke8 (AUTHOR), Madden, Cynthia8 (AUTHOR), Cuyper, Dirk de9 (AUTHOR), Davies, Owen10 (AUTHOR), Thaçi, Diamant11 (AUTHOR) |
| Source: | British Journal of Dermatology. Apr2024, Vol. 190 Issue 4, p477-485. 9p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
